BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12189228)

  • 21. Hyperforin in St. John's wort drug interactions.
    Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
    Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of St John's wort (Hypericum perforatum L.) extract on plasma androgen concentrations in healthy men and women: a pilot study.
    Donovan JL; DeVane CL; Lewis JG; Wang JS; Ruan Y; Chavin KD; Markowitz JS
    Phytother Res; 2005 Oct; 19(10):901-6. PubMed ID: 16261523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers.
    Lei HP; Yu XY; Xie HT; Li HH; Fan L; Dai LL; Chen Y; Zhou HH
    Xenobiotica; 2010 Apr; 40(4):275-81. PubMed ID: 20102294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. St. John's wort and irinotecan-induced diarrhea.
    Birdsall TC
    Toxicol Appl Pharmacol; 2007 Apr; 220(1):108; author reply 109-10. PubMed ID: 17276473
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
    Mai I; Bauer S; Perloff ES; Johne A; Uehleke B; Frank B; Budde K; Roots I
    Clin Pharmacol Ther; 2004 Oct; 76(4):330-40. PubMed ID: 15470332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers.
    Burstein AH; Horton RL; Dunn T; Alfaro RM; Piscitelli SC; Theodore W
    Clin Pharmacol Ther; 2000 Dec; 68(6):605-12. PubMed ID: 11180020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug interaction between St. John's wort and cyclosporine.
    Barone GW; Gurley BJ; Ketel BL; Lightfoot ML; Abul-Ezz SR
    Ann Pharmacother; 2000 Sep; 34(9):1013-6. PubMed ID: 10981246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.
    Moore LB; Goodwin B; Jones SA; Wisely GB; Serabjit-Singh CJ; Willson TM; Collins JL; Kliewer SA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7500-2. PubMed ID: 10852961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
    Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of pharmacokinetic interaction between St. John's wort and prednisone.
    Bell EC; Ravis WR; Chan HM; Lin YJ
    Ann Pharmacother; 2007 Nov; 41(11):1819-24. PubMed ID: 17925494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
    Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
    Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of St John's Wort on CYP2C19 activity with respect to genotype.
    Wang LS; Zhu B; Abd El-Aty AM; Zhou G; Li Z; Wu J; Chen GL; Liu J; Tang ZR; An W; Li Q; Wang D; Zhou HH
    J Clin Pharmacol; 2004 Jun; 44(6):577-81. PubMed ID: 15145964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort.
    Qi JW; Nakamura K; Hosokawa S; Okada Y; Horiuchi R; Yamamoto K
    Biol Pharm Bull; 2005 Aug; 28(8):1467-71. PubMed ID: 16079494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.
    Wenk M; Todesco L; Krähenbühl S
    Br J Clin Pharmacol; 2004 Apr; 57(4):495-9. PubMed ID: 15025748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interaction between St John's wort and zolpidem in healthy subjects.
    Hojo Y; Echizenya M; Ohkubo T; Shimizu T
    J Clin Pharm Ther; 2011 Dec; 36(6):711-5. PubMed ID: 21058968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic interactions of drugs with St John's wort.
    Zhou S; Chan E; Pan SQ; Huang M; Lee EJ
    J Psychopharmacol; 2004 Jun; 18(2):262-76. PubMed ID: 15260917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phytotherapy threats with emphasis on St. John's wort medicines].
    Sienkiewicz J; Czarnik-Matusewicz H; Wiela-Hojeńska A
    Pol Merkur Lekarski; 2013 Nov; 35(209):309-12. PubMed ID: 24575655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
    Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
    Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. St John's wort greatly decreases the plasma concentrations of oral S-ketamine.
    Peltoniemi MA; Saari TI; Hagelberg NM; Laine K; Neuvonen PJ; Olkkola KT
    Fundam Clin Pharmacol; 2012 Dec; 26(6):743-50. PubMed ID: 21635359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.